Clinical Trial: Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational




Official Title: Urinary Biomarker NGAL in Decompensated Cirrhosis: Early Prediction of AKI and of Treatment Response

Brief Summary: The purpose of this study is to test the accuracy of urinary neutrophil-gelatinase associated lipocalin (NGAL) and other biomarkers (plasma renin, norepinephrine) to predict acute kidney injury (AKI) development in patients with cirrhosis and bacterial infection and to predict response to AKI treatment with albumin and albumin with terlipressin in patients with suspected hepatorenal syndrome.